Physician profile
Frances Hull
NPI 1336531870
$5,842.12
in general payments reported to CMS, 2019-2025
39 companies · $1,678 in 2025
The $1,678 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $257 · 2022: $931 · 2023: $1,556 · 2024: $1,421 · 2025: $1,678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,654.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,211.65 | 2021-2025 | Farxiga, Breztri, Lokelma |
| Abbvie INC. | $901.95 | 2022-2025 | |
| Pfizer INC. | $571.05 | 2023-2025 | |
| Novo Nordisk INC | $386.78 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $358.30 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $269.17 | 2021-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $221.34 | 2024-2025 | Entyvio, Gattex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.47 | 2022-2025 | Jardiance, Synjardy |
| Xeris Pharmaceuticals, INC. | $200.82 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Astellas Pharma US INC | $171.48 | 2023-2024 | Veozah |
| Neurocrine Biosciences, INC. | $121.94 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $116.20 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $111.13 | 2023-2025 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $110.47 | 2022 | |
| Amgen INC. | $74.48 | 2022-2025 | Repatha, Otezla, Otezla |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frances Hull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.